ID   TXTP_HUMAN              Reviewed;         311 AA.
AC   P53007; A8K8E8; Q9BSK6;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-FEB-2002, sequence version 2.
DT   07-APR-2021, entry version 196.
DE   RecName: Full=Tricarboxylate transport protein, mitochondrial;
DE   AltName: Full=Citrate transport protein;
DE            Short=CTP;
DE   AltName: Full=Solute carrier family 25 member 1;
DE   AltName: Full=Tricarboxylate carrier protein;
DE   Flags: Precursor;
GN   Name=SLC25A1; Synonyms=SLC20A3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8666394; DOI=10.1006/geno.1995.9982;
RA   Heisterkamp N., Mulder M.P., Langeveld A., ten Hoeve J., Wang Z., Roe B.,
RA   Groffen J.;
RT   "Localization of the human mitochondrial citrate transporter protein gene
RT   to chromosome 22q11 in the DiGeorge syndrome critical region.";
RL   Genomics 29:451-456(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Brain;
RX   PubMed=8660975; DOI=10.1006/geno.1996.0191;
RA   Goldmuntz E., Wang Z., Roe B.A., Budarf M.L.;
RT   "Cloning, genomic organization, and chromosomal localization of human
RT   citrate transport protein to the DiGeorge/velocardiofacial syndrome minimal
RT   critical region.";
RL   Genomics 33:271-276(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-156, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [8]
RP   FUNCTION, INVOLVEMENT IN CMS23, AND VARIANT CMS23 GLN-247.
RX   PubMed=26870663; DOI=10.3233/jnd-140021;
RA   Chaouch A., Porcelli V., Cox D., Edvardson S., Scarcia P., De Grassi A.,
RA   Pierri C.L., Cossins J., Laval S.H., Griffin H., Mueller J.S.,
RA   Evangelista T., Toepf A., Abicht A., Huebner A., von der Hagen M.,
RA   Bushby K., Straub V., Horvath R., Elpeleg O., Palace J., Senderek J.,
RA   Beeson D., Palmieri L., Lochmueller H.;
RT   "Mutations in the mitochondrial citrate carrier SLC25A1 are associated with
RT   impaired neuromuscular transmission.";
RL   J. Neuromuscul. Dis. 1:75-90(2014).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [11]
RP   FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES, CHARACTERIZATION OF VARIANTS
RP   D2L2AD LEU-45; ASP-130; GLN-144; TRP-193; HIS-198; THR-202; CYS-282;
RP   GLY-282; HIS-282 AND CYS-297, AND CHARACTERIZATION OF VARIANT CMS23
RP   GLN-247.
RX   PubMed=29031613; DOI=10.1016/j.bbabio.2017.10.002;
RA   Majd H., King M.S., Smith A.C., Kunji E.R.S.;
RT   "Pathogenic mutations of the human mitochondrial citrate carrier SLC25A1
RT   lead to impaired citrate export required for lipid, dolichol, ubiquinone
RT   and sterol synthesis.";
RL   Biochim. Biophys. Acta 1859:1-7(2018).
RN   [12]
RP   FUNCTION, VARIANTS D2L2AD THR-28; ASN-40; LYS-47; ASP-93; TRP-193 AND
RP   ARG-262, AND CHARACTERIZATION OF VARIANTS D2L2AD THR-28; ASN-40; LYS-47;
RP   ASP-93; TRP-193; 256-TYR--ASP-311 DEL AND ARG-262.
RX   PubMed=29238895; DOI=10.1007/s10545-017-0106-7;
RA   Pop A., Williams M., Struys E.A., Monne M., Jansen E.E.W., De Grassi A.,
RA   Kanhai W.A., Scarcia P., Ojeda M.R.F., Porcelli V., van Dooren S.J.M.,
RA   Lennertz P., Nota B., Abdenur J.E., Coman D., Das A.M., El-Gharbawy A.,
RA   Nuoffer J.M., Polic B., Santer R., Weinhold N., Zuccarelli B., Palmieri F.,
RA   Palmieri L., Salomons G.S.;
RT   "An overview of combined D-2- and L-2-hydroxyglutaric aciduria: functional
RT   analysis of CIC variants.";
RL   J. Inherit. Metab. Dis. 41:169-180(2018).
RN   [13]
RP   VARIANTS D2L2AD LEU-45; GLN-144; ARG-167; TRP-193; THR-202;
RP   256-TYR--ASP-311 DEL; CYS-282; GLY-282 AND CYS-297, AND CHARACTERIZATION OF
RP   VARIANT D2L2AD 256-TYR--ASP-311 DEL.
RX   PubMed=23561848; DOI=10.1016/j.ajhg.2013.03.009;
RA   Nota B., Struys E.A., Pop A., Jansen E.E., Fernandez Ojeda M.R.,
RA   Kanhai W.A., Kranendijk M., van Dooren S.J., Bevova M.R., Sistermans E.A.,
RA   Nieuwint A.W., Barth M., Ben-Omran T., Hoffmann G.F., de Lonlay P.,
RA   McDonald M.T., Meberg A., Muntau A.C., Nuoffer J.M., Parini R., Read M.H.,
RA   Renneberg A., Santer R., Strahleck T., van Schaftingen E.,
RA   van der Knaap M.S., Jakobs C., Salomons G.S.;
RT   "Deficiency in SLC25A1, encoding the mitochondrial citrate carrier, causes
RT   combined D-2- and L-2-hydroxyglutaric aciduria.";
RL   Am. J. Hum. Genet. 92:627-631(2013).
RN   [14]
RP   VARIANTS D2L2AD ASP-130 AND HIS-282.
RX   PubMed=23393310; DOI=10.1136/jmedgenet-2012-101485;
RA   Edvardson S., Porcelli V., Jalas C., Soiferman D., Kellner Y., Shaag A.,
RA   Korman S.H., Pierri C.L., Scarcia P., Fraenkel N.D., Segel R.,
RA   Schechter A., Frumkin A., Pines O., Saada A., Palmieri L., Elpeleg O.;
RT   "Agenesis of corpus callosum and optic nerve hypoplasia due to mutations in
RT   SLC25A1 encoding the mitochondrial citrate transporter.";
RL   J. Med. Genet. 50:240-245(2013).
RN   [15]
RP   VARIANT D2L2AD LEU-45.
RX   PubMed=25614306; DOI=10.1007/8904_2014_378;
RA   Prasun P., Young S., Salomons G., Werneke A., Jiang Y.H., Struys E.,
RA   Paige M., Avantaggiati M.L., McDonald M.;
RT   "Expanding the clinical spectrum of mitochondrial citrate carrier (SLC25A1)
RT   deficiency: Facial dysmorphism in siblings with epileptic encephalopathy
RT   and combined D,L-2-hydroxyglutaric aciduria.";
RL   JIMD Rep. 19:111-115(2015).
RN   [16]
RP   VARIANT D2L2AD HIS-198.
RX   PubMed=27306203; DOI=10.1007/8904_2016_536;
RG   FORGE Canada Consortium;
RA   Smith A., McBride S., Marcadier J.L., Michaud J., Al-Dirbashi O.Y.,
RA   Schwartzentruber J., Beaulieu C.L., Katz S.L., Majewski J., Bulman D.E.,
RA   Geraghty M.T., Harper M.E., Chakraborty P., Lines M.A.;
RT   "Severe neonatal presentation of mitochondrial citrate carrier (SLC25A1)
RT   deficiency.";
RL   JIMD Rep. 30:73-79(2016).
RN   [17]
RP   VARIANT D2L2AD SER-238.
RX   PubMed=29226520; DOI=10.1002/ajmg.a.38574;
RA   Cohen I., Staretz-Chacham O., Wormser O., Perez Y., Saada A., Kadir R.,
RA   Birk O.S.;
RT   "A novel homozygous SLC25A1 mutation with impaired mitochondrial complex V:
RT   Possible phenotypic expansion.";
RL   Am. J. Med. Genet. A 176:330-336(2018).
CC   -!- FUNCTION: Citrate transporter that mediates the exchange of
CC       mitochondrial citrate for cytosolic malate (PubMed:29031613,
CC       PubMed:29238895). Also able to mediate the exchange of citrate for
CC       isocitrate, phosphoenolpyruvate, cis- but not trans-aconitate and to a
CC       lesser extend maleate and succinate (PubMed:29031613). Important for
CC       the bioenergetics of hepatic cells as it provides a carbon source for
CC       fatty acid and sterol biosyntheses, and NAD(+) for the glycolytic
CC       pathway. Required for proper neuromuscular junction formation
CC       (Probable). {ECO:0000269|PubMed:29031613, ECO:0000269|PubMed:29238895,
CC       ECO:0000305|PubMed:26870663}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=7.5 uM for citrate {ECO:0000269|PubMed:29031613};
CC   -!- SUBCELLULAR LOCATION: Mitochondrion inner membrane
CC       {ECO:0000250|UniProtKB:Q8JZU2}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- DISEASE: Combined D-2- and L-2-hydroxyglutaric aciduria (D2L2AD)
CC       [MIM:615182]: An autosomal recessive neurometabolic disorder
CC       characterized by neonatal-onset encephalopathy with severe muscular
CC       weakness, intractable seizures, respiratory distress, and lack of
CC       psychomotor development resulting in early death. Brain imaging shows
CC       abnormalities including enlarged ventricles, delayed myelination, and
CC       germinal layer cysts. {ECO:0000269|PubMed:23393310,
CC       ECO:0000269|PubMed:23561848, ECO:0000269|PubMed:25614306,
CC       ECO:0000269|PubMed:27306203, ECO:0000269|PubMed:29031613,
CC       ECO:0000269|PubMed:29226520, ECO:0000269|PubMed:29238895}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 23, presynaptic (CMS23)
CC       [MIM:618197]: A form of congenital myasthenic syndrome, a group of
CC       disorders characterized by failure of neuromuscular transmission,
CC       including pre-synaptic, synaptic, and post-synaptic disorders that are
CC       not of autoimmune origin. Clinical features include easy fatigability
CC       and muscle weakness. CMS23 inheritance is autosomal recessive.
CC       {ECO:0000269|PubMed:26870663, ECO:0000269|PubMed:29031613}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the mitochondrial carrier (TC 2.A.29) family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U25147; AAB08515.1; -; mRNA.
DR   EMBL; L76134; AAL40091.1; -; Genomic_DNA.
DR   EMBL; L75823; AAL40090.1; -; mRNA.
DR   EMBL; AK292313; BAF85002.1; -; mRNA.
DR   EMBL; BC004980; AAH04980.1; -; mRNA.
DR   EMBL; BC008061; AAH08061.1; -; mRNA.
DR   CCDS; CCDS13758.1; -.
DR   PIR; G01789; G01789.
DR   RefSeq; NP_005975.1; NM_005984.4.
DR   BioGRID; 112464; 187.
DR   IntAct; P53007; 80.
DR   MINT; P53007; -.
DR   STRING; 9606.ENSP00000215882; -.
DR   DrugBank; DB09154; Sodium citrate.
DR   TCDB; 2.A.29.7.2; the mitochondrial carrier (mc) family.
DR   iPTMnet; P53007; -.
DR   PhosphoSitePlus; P53007; -.
DR   SwissPalm; P53007; -.
DR   BioMuta; SLC25A1; -.
DR   DMDM; 20141931; -.
DR   CPTAC; CPTAC-586; -.
DR   CPTAC; CPTAC-587; -.
DR   EPD; P53007; -.
DR   jPOST; P53007; -.
DR   MassIVE; P53007; -.
DR   MaxQB; P53007; -.
DR   PaxDb; P53007; -.
DR   PeptideAtlas; P53007; -.
DR   PRIDE; P53007; -.
DR   ProteomicsDB; 56567; -.
DR   TopDownProteomics; P53007; -.
DR   Antibodypedia; 22859; 139 antibodies.
DR   DNASU; 6576; -.
DR   Ensembl; ENST00000215882; ENSP00000215882; ENSG00000100075.
DR   GeneID; 6576; -.
DR   KEGG; hsa:6576; -.
DR   UCSC; uc002zoz.6; human.
DR   CTD; 6576; -.
DR   DisGeNET; 6576; -.
DR   GeneCards; SLC25A1; -.
DR   GeneReviews; SLC25A1; -.
DR   HGNC; HGNC:10979; SLC25A1.
DR   HPA; ENSG00000100075; Low tissue specificity.
DR   MalaCards; SLC25A1; -.
DR   MIM; 190315; gene.
DR   MIM; 615182; phenotype.
DR   MIM; 618197; phenotype.
DR   neXtProt; NX_P53007; -.
DR   OpenTargets; ENSG00000100075; -.
DR   Orphanet; 356978; D,L-2-hydroxyglutaric aciduria.
DR   Orphanet; 98914; Presynaptic congenital myasthenic syndromes.
DR   PharmGKB; PA35855; -.
DR   VEuPathDB; HostDB:ENSG00000100075.9; -.
DR   eggNOG; KOG0756; Eukaryota.
DR   GeneTree; ENSGT00550000074856; -.
DR   HOGENOM; CLU_015166_5_1_1; -.
DR   InParanoid; P53007; -.
DR   OMA; FLSNKMR; -.
DR   PhylomeDB; P53007; -.
DR   TreeFam; TF105786; -.
DR   PathwayCommons; P53007; -.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   Reactome; R-HSA-75105; Fatty acyl-CoA biosynthesis.
DR   BioGRID-ORCS; 6576; 60 hits in 993 CRISPR screens.
DR   ChiTaRS; SLC25A1; human.
DR   GeneWiki; SLC25A1; -.
DR   GenomeRNAi; 6576; -.
DR   Pharos; P53007; Tbio.
DR   PRO; PR:P53007; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; P53007; protein.
DR   Bgee; ENSG00000100075; Expressed in liver and 231 other tissues.
DR   ExpressionAtlas; P53007; baseline and differential.
DR   Genevisible; P53007; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0071913; F:citrate secondary active transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015137; F:citrate transmembrane transporter activity; TAS:UniProtKB.
DR   GO; GO:0046949; P:fatty-acyl-CoA biosynthetic process; TAS:Reactome.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0006843; P:mitochondrial citrate transmembrane transport; IBA:GO_Central.
DR   Gene3D; 1.50.40.10; -; 1.
DR   InterPro; IPR002067; Mit_carrier.
DR   InterPro; IPR018108; Mitochondrial_sb/sol_carrier.
DR   InterPro; IPR023395; Mt_carrier_dom_sf.
DR   Pfam; PF00153; Mito_carr; 3.
DR   PRINTS; PR00926; MITOCARRIER.
DR   SUPFAM; SSF103506; SSF103506; 1.
DR   PROSITE; PS50920; SOLCAR; 3.
PE   1: Evidence at protein level;
KW   Congenital myasthenic syndrome; Disease variant; Membrane; Mitochondrion;
KW   Mitochondrion inner membrane; Phosphoprotein; Reference proteome; Repeat;
KW   Transit peptide; Transmembrane; Transmembrane helix; Transport.
FT   TRANSIT         1..13
FT                   /note="Mitochondrion"
FT                   /evidence="ECO:0000250|UniProtKB:P32089"
FT   CHAIN           14..311
FT                   /note="Tricarboxylate transport protein, mitochondrial"
FT                   /id="PRO_0000019262"
FT   TRANSMEM        29..46
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        86..105
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        129..143
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        183..202
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        224..241
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        278..297
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   REPEAT          23..111
FT                   /note="Solcar 1"
FT   REPEAT          122..208
FT                   /note="Solcar 2"
FT   REPEAT          218..303
FT                   /note="Solcar 3"
FT   MOD_RES         156
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VARIANT         28
FT                   /note="A -> T (in D2L2AD; unknown pathological
FT                   significance; very mild decrease of citrate transport
FT                   rates)"
FT                   /evidence="ECO:0000269|PubMed:29238895"
FT                   /id="VAR_081661"
FT   VARIANT         40
FT                   /note="I -> N (in D2L2AD; reduced rates of citrate
FT                   transport)"
FT                   /evidence="ECO:0000269|PubMed:29238895"
FT                   /id="VAR_081662"
FT   VARIANT         45
FT                   /note="P -> L (in D2L2AD; severely reduced rates of citrate
FT                   transport)"
FT                   /evidence="ECO:0000269|PubMed:23561848,
FT                   ECO:0000269|PubMed:25614306, ECO:0000269|PubMed:29031613"
FT                   /id="VAR_069490"
FT   VARIANT         47
FT                   /note="E -> K (in D2L2AD; severely reduced rates of citrate
FT                   transport; dbSNP:rs1555923307)"
FT                   /evidence="ECO:0000269|PubMed:29238895"
FT                   /id="VAR_081663"
FT   VARIANT         93
FT                   /note="G -> D (in D2L2AD; severely reduced rates of citrate
FT                   transport)"
FT                   /evidence="ECO:0000269|PubMed:29238895"
FT                   /id="VAR_081664"
FT   VARIANT         130
FT                   /note="G -> D (in D2L2AD; severely reduced rates of citrate
FT                   transport; dbSNP:rs368647424)"
FT                   /evidence="ECO:0000269|PubMed:23393310,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_081665"
FT   VARIANT         144
FT                   /note="E -> Q (in D2L2AD; abolishes citrate transport)"
FT                   /evidence="ECO:0000269|PubMed:23561848,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_069491"
FT   VARIANT         167
FT                   /note="G -> R (in D2L2AD)"
FT                   /evidence="ECO:0000269|PubMed:23561848"
FT                   /id="VAR_069492"
FT   VARIANT         193
FT                   /note="S -> W (in D2L2AD; reduced rates of citrate
FT                   transport; dbSNP:rs781925968)"
FT                   /evidence="ECO:0000269|PubMed:23561848,
FT                   ECO:0000269|PubMed:29031613, ECO:0000269|PubMed:29238895"
FT                   /id="VAR_069493"
FT   VARIANT         198
FT                   /note="R -> H (in D2L2AD; severely reduced rates of citrate
FT                   transport; dbSNP:rs1331417017)"
FT                   /evidence="ECO:0000269|PubMed:27306203,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_077511"
FT   VARIANT         202
FT                   /note="M -> T (in D2L2AD; reduced rates of citrate
FT                   transport; dbSNP:rs782335811)"
FT                   /evidence="ECO:0000269|PubMed:23561848,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_069494"
FT   VARIANT         238
FT                   /note="N -> S (in D2L2AD; disease phenotype may include
FT                   decreased activity of mitochondrial respiratory chain
FT                   complex V)"
FT                   /evidence="ECO:0000269|PubMed:29226520"
FT                   /id="VAR_081666"
FT   VARIANT         247
FT                   /note="R -> Q (in CMS23; reduced rates of citrate
FT                   transport; dbSNP:rs781908532)"
FT                   /evidence="ECO:0000269|PubMed:26870663,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_081667"
FT   VARIANT         256..311
FT                   /note="Missing (in D2L2AD; no protein detected by Western
FT                   blot in patient fibroblasts; severely reduced rates of
FT                   citrate transport)"
FT                   /evidence="ECO:0000269|PubMed:23561848,
FT                   ECO:0000269|PubMed:29238895"
FT                   /id="VAR_081668"
FT   VARIANT         262
FT                   /note="C -> R (in D2L2AD; reduced rates of citrate
FT                   transport)"
FT                   /evidence="ECO:0000269|PubMed:29238895"
FT                   /id="VAR_081669"
FT   VARIANT         282
FT                   /note="R -> C (in D2L2AD; abolishes citrate transport;
FT                   dbSNP:rs431905509)"
FT                   /evidence="ECO:0000269|PubMed:23561848,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_069495"
FT   VARIANT         282
FT                   /note="R -> G (in D2L2AD; abolishes citrate transport;
FT                   dbSNP:rs431905509)"
FT                   /evidence="ECO:0000269|PubMed:23561848,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_069496"
FT   VARIANT         282
FT                   /note="R -> H (in D2L2AD; abolishes citrate transport;
FT                   dbSNP:rs431905510)"
FT                   /evidence="ECO:0000269|PubMed:23393310,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_081670"
FT   VARIANT         297
FT                   /note="Y -> C (in D2L2AD; reduced rates of citrate
FT                   transport)"
FT                   /evidence="ECO:0000269|PubMed:23561848,
FT                   ECO:0000269|PubMed:29031613"
FT                   /id="VAR_069497"
FT   CONFLICT        26
FT                   /note="G -> E (in Ref. 1; AAB08515)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   311 AA;  34013 MW;  F1341629924953D6 CRC64;
     MPAPRAPRAL AAAAPASGKA KLTHPGKAIL AGGLAGGIEI CITFPTEYVK TQLQLDERSH
     PPRYRGIGDC VRQTVRSHGV LGLYRGLSSL LYGSIPKAAV RFGMFEFLSN HMRDAQGRLD
     STRGLLCGLG AGVAEAVVVV CPMETIKVKF IHDQTSPNPK YRGFFHGVRE IVREQGLKGT
     YQGLTATVLK QGSNQAIRFF VMTSLRNWYR GDNPNKPMNP LITGVFGAIA GAASVFGNTP
     LDVIKTRMQG LEAHKYRNTW DCGLQILKKE GLKAFYKGTV PRLGRVCLDV AIVFVIYDEV
     VKLLNKVWKT D
//
